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Introduction: The cholinergic system is involved in learning and memory and is affected in neurodegenerative
disorders such as Alzheimer's disease. The possibility of non-invasively detecting alterations of neurotransmitter
systems in the mouse brain would greatly improve early diagnosis and treatment strategies. The hypothesis of
this study is that acutemodulation of the cholinergic systemmight be reﬂected as altered functional connectivity
(FC) and can be measured using pharmacological resting-state functional MRI (rsfMRI).
Material andmethods: Pharmacological rsfMRIwas performed on a 9.4 TMRI scanner (Bruker BioSpec, Germany)
using a gradient echo EPI sequence. All mice were sedated with medetomidine. C57BL/6 mice (N= 15/group)
were injected with either saline, the cholinergic antagonist scopolamine, or methyl-scopolamine, after which
rsfMRI was acquired. For an additional group (N = 8), rsfMRI scans of the same mouse were acquired ﬁrst at
baseline, then after the administration of scopolamine and ﬁnally after the additional injection of the cholinergic
agonistmilameline. Contextualmemorywas evaluatedwith the same setup as the pharmacological rsfMRI using
the passive avoidance behavior test.
Results: Scopolamine induced a dose-dependent decrease of FC between brain regions involved in memory.
Scopolamine-induced FC deﬁcits could be recovered completely by milameline for FC between the hippocampus–
thalamus, cingulate–retrosplenial, and visual–retrosplenial cortex. FC between the cingulate–rhinal, cingulate–
visual and visual–rhinal cortex could not be completely recovered by milameline. This is consistent with the
behavioral outcome, where milameline only partially recovered scopolamine-induced contextual memory
deﬁcits. Methyl-scopolamine administered at the same dose as scopolamine did not affect FC in the brain.
Conclusion: The results of the current study are important for future studies in mouse models of neurodegenera-
tive disorders, where pharmacological rsfMRI may possibly be used as a non-invasive read-out tool to detect
alterations of neurotransmitter systems induced by pathology or treatment.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Impairments of neurotransmitter systems are a common feature of
neurodegenerative disorders and occur at early stages of disease pro-
gression. These deﬁcits of neurotransmitter systems lead to impaired
communication between brain regions and eventually behavior disrup-
tions at later stages (Penzes et al., 2013; van Spronsen and Hoogenraad,
2010). For example, in Alzheimer's disease (AD) itwas reported that the
toxic effects of amyloid pathology and inﬂammation induce synaptic
defects in the cortex and hippocampus, eventually leading to cognitive.
. This is an open access article underdysfunctions (Spires-Jones and Knafo, 2012). The neurotransmitter
system that is most severely affected in AD is the cholinergic system.
The cholinergic network is important for learning and memory,
functions that are affected in AD patients (Schneider et al., 2014). The
pathological phenotypes are probably a consequence of a complex in-
terplay of events that develop over time. The existence ofmousemodels
of neurological disorders allows studying how speciﬁc aspects of
pathology affect neurotransmitter systems. Therefore, a non-invasive
tool that enables the detection of modulated neurotransmitter systems
in themouse brainwould greatly improve the efﬁcacy of early diagnosis
and support the development of new treatment strategies.
Functional magnetic resonance imaging (fMRI) techniques have
gained a signiﬁcant role in improving our understanding of brain func-
tion. Resting-state functionalMRI (rsfMRI) is used to evaluate functionalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
152 D. Shah et al. / NeuroImage 109 (2015) 151–159connectivity (FC) in the brain and was ﬁrst described by Biswal et al.
(1995). They showed that stimulation of the motor cortex by hand
movement revealed activation, i.e. increased blood oxygenation, of
motor areas in the human brain. During rest, the time courses of the
blood-oxygenation-level-dependent (BOLD) signal of these motor
areas correlated in the lower frequencies (0.01–0.1 Hz). They concluded
that this correlation of low frequency ﬂuctuations of blood oxygenation
between brain regions during rest could be a manifestation of brain FC.
The great advantage of rsfMRI is its non-invasive character and relative-
ly high spatial and temporal resolution. It has been applied to study
diseases in the human brain (Buckner et al., 2008; Sheline and Raichle,
2013; van den Heuvel and Hulshoff Pol, 2010) and recently also the
healthy (Jonckers et al., 2011; Lu et al., 2012) and diseased (Shah
et al., 2013) rodent brain.
Previous studies in human subjects demonstrated that decreasing
cholinergic neurotransmission with a cholinergic antagonist affects
the BOLD signal in the hippocampus (Antonova et al., 2011; Sperling
et al., 2002). AD patients, who display severe deﬁcits of cholinergic syn-
apses and loss of cholinergic neurons (Bales et al., 2006; Pepeu and
Giovannini, 2004; Schneider et al., 2014; Watanabe et al., 2009), show
altered FC in cortical regions and the hippocampus (Sheline and
Raichle, 2013). Furthermore, stimulating the cholinergic system in AD
patients increased FC in the cortex (Li et al., 2012) and hippocampus
(Pa et al., 2013; Risacher et al., 2013). RsfMRI studies targeting the
cholinergic system in rodents are still quite limited. However, an fMRI
study in rats showed altered brain activity in frontal brain regions
after diminishing cholinergic neurotransmission (Kocsis et al., 2014).
This study aims to detect the effects of acute pharmacological
modulations of the cholinergic system on FC in the mouse brain.
Because modulating neurotransmission implies that brain function is
changed before the rsfMRI acquisition, the term ‘resting-state’ might
not be applicable in this context. Therefore, we refer to this concept as
pharmacological rsfMRI. The present study investigates the effects of
scopolamine, a muscarinic acetylcholine receptor (mAChR) antagonist,
on brain FC in a dose-dependent manner and evaluates whether
scopolamine-induced FC deﬁcits can be reversed using a mAChR
agonist, milameline. This is the ﬁrst study showing the ability of
pharmacological rsfMRI to detect cholinergic modulations in the
mouse brain.
Material and methods
Animals and ethics statement
Male C57BL/6mice of 12weeks oldwere used throughout thewhole
study (C57BL/6, Jax mice strain, Charles River Laboratories). All proce-
dures were performed in strict accordance with the European Directive
2010/63/EU on the protection of animals used for scientiﬁc purposes.
The protocols were approved by the Committee on Animal Care and
Use at the University of Antwerp, Belgium (permit number 2012-48)
and all efforts were made to minimize animal suffering.
MRI procedures
For the handling procedures the mice were anesthetized with 2%
isoﬂurane (IsoFlo, Abbott, Illinois, USA), which was administered in a
mixture of 70% N2 and 30% O2. A subcutaneous (s.c.) catheter was
used to administer saline, scopolamine (scopolamine hydrobromide
trihydrate, Sigma Aldrich), milameline (milameline hydrochloride,
Santa Cruz Biotechnology) or methyl-scopolamine (scopolamine
methyl bromide, Sigma Aldrich). The physiological status of all animals
wasmonitored throughout the imaging procedure. A pressure sensitive
pad (MR-compatible Small Animal Monitoring and Gating system, SA
Instruments, Inc.) was used to monitor breathing rate and a rectal
thermistorwith feedback controlledwarmair circuitry (MR-compatible
Small Animal Heating System, SA Instruments, Inc.) was used tomaintain body temperature at (37.0 ± 0.5) °C. During the phMRI
and rsfMRI imaging procedures, medetomidine (Domitor, Pﬁzer,
Karlsruhe, Germany) was used to sedate the animals as previously
described (Jonckers et al., 2011). After the imaging procedures, the
effects of medetomidine were counteracted by injecting of 0.1 mg/kg
atipamezole (Antisedan, Pﬁzer, Karlsruhe, Germany).
MRI procedures were performed on a 9.4 T Biospec MRI system
(Bruker BioSpin, Germany) with the Paravision 5.1 software (www.
bruker.com). Images were acquired using a standard Bruker cross coil
setup with a quadrature volume coil and a quadrature surface coil for
mice. Three orthogonal multi-slice Turbo RARE T2-weighted images
were acquired to render slice-positioning uniform (repetition time
2000 ms, echo time 15 ms, 16 slices of 0.4 mm). Field maps were
acquired for each animal to assess ﬁeld homogeneity, followed by
local shimming, which corrects for the measured inhomogeneity in a
rectangular VOI within the brain.
Pharmacological MRI
PhMRI (N=8mice) was performed to determine inwhich brain re-
gions scopolamine induces signal intensity changes. PhMRI data were
acquired using a T2*-weighted echo planar imaging (EPI) sequence
(repetition time 15,000 ms, echo time 25 ms, 16 slices of 0.4 mm, 240
repetitions). The ﬁeld-of-view was (20 × 20) mm2 and the matrix size
was (128 × 64), resulting in voxel dimensions of (0.156 × 0.312)
mm2. Baseline scans were acquired for 15 min (60 repetitions) after
which either saline (10 ml/kg, s.c.) or scopolamine (3 mg/kg, s.c.)
was administered through a catheter (injected volumes 0.3 ml) and
scanning continued until 45 min (180 repetitions) post-injection.
Pharmacological resting-state functional MRI
Resting-state signals were measured using a T2*-weighted single
shot EPI sequence (repetition time 2000 ms, echo time 15 ms, 16 slices
of 0.4 mm, 150 repetitions). The ﬁeld-of-view was (20 × 20) mm2 and
the matrix size was (128 × 64), resulting in voxel dimensions of
(0.156 × 0.312) mm2. Mice (N = 15/group) were injected with either
saline (10 ml/kg, s.c.), scopolamine (0.5 mg/kg;1 mg/kg;3 mg/kg, s.c.),
milameline (1 mg/kg, s.c.) or methyl-scopolamine (3 mg/kg, s.c.)
(injected volumes 0.3ml). Pharmacological rsfMRI scans were acquired
25 min post-injection to ensure that the pharmacological substances
have reached the brain.
Another group of mice (N = 10) were subjected to the following
protocol: baseline pharmacological rsfMRI scans were acquired, after
which scopolamine (1mg/kg, s.c.) was administered and pharmacolog-
ical rsfMRI scans were acquired again 25min later. Then, themice were
injected with milameline (1 mg/kg, s.c.) and pharmacological rsfMRI
scans were taken 25 min after the milameline injection (injected
volumes 0.3 ml). To take into consideration that the observed FC
recovery might be due to scopolamine wash-out instead of milameline
administration, an additional group of scopolamine-injected (1 mg/kg,
s.c.) mice were subjected to pharmacological rsfMRI scans 60 min
after scopolamine injection.
MRI data pre-processing
Pre-processing of the phMRI and rsfMRI data, including realignment,
normalization and smoothing, was performed using SPM8 software
(Statistical Parametric Mapping, http://www.ﬁl.ion.ucl.ac.uk). First, all
images within each session were realigned to the ﬁrst image. This was
done using a least-squares approach and a 6-parameter (rigid body)
spatial transformation. Second, all datasets were normalized to a
study speciﬁc EPI template. The normalization steps consist of a global
12-parameter afﬁne transformation followed by the estimation of the
nonlinear deformations. Finally, in plane smoothing was done using a
Gaussian kernel with full width at half maximum of twice the voxel
size (Jonckers et al., 2011).
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Pharmacological MRI
The phMRI data analysis was performed in SPM8. For each animal
the smoothed data were ﬁtted to a generalized linear model (GLM) in
which the motion parameters, resulting from the realignment, were
included as covariates to account for movement. For each animal two
conditions were compared: the ﬁrst 60 repetitions (pre-injection) and
the last 100 repetitions (20 min post-injection). Mean statistical
difference images of the pre-injection vs. post-injection conditions
were computed for the saline and scopolamine group in SPM8 and
presented by overlaying them on an EPI image.
Pharmacological resting-state functional MRI: ROI-based analysis
The REST toolbox (REST1.7, http://resting-fmri.sourceforge.net)
was used to analyze the pharmacological rsfMRI data. The smoothed
data and a mask for each ROI (the orbitofrontal cortex, the cingulate
cortex, the somatosensory cortex, the thalamus, the hippocampus, the
retrosplenial cortex, the rhinal cortex, the auditory cortex, the visual
cortex and the ventral tegmental are/substantia nigra) were loaded
into the software and themotion parameters resulting from the realign-
mentwere included as covariates to correct for possiblemovement that
occurred during the scanning procedure. The ﬁlter was set between
0.01 and 0.1 Hz to retain the low frequency ﬂuctuations of the time
course of the BOLD-signal that are of interest when performing
FC studies. The time courses of the BOLD-signal were extracted
for each ROI and correlation coefﬁcients between the time traces of
each pair of ROIs were calculated. These correlation coefﬁcients were
z-transformed using an in-house program developed in MATLAB
(MATLAB R2013a, TheMathWorks Inc. Natick,MA, USA) and represent-
ed in a correlationmatrix. Mean z-transformed FCmatrices were calcu-
lated for each group of mice i.e. the saline, scopolamine andmilameline
group.
Pharmacological resting-state functional MRI: seed-based correlation
analysis
Using the REST-toolbox, individual z-transformed FC-maps were
obtained for all saline, methyl-scopolamine and scopolamine-treated
animals with the left hippocampus, cingulate cortex or visual cortex as
seed regions. The samewas done for all animals of which pharmacolog-
ical rsfMRI scans were acquired at baseline and after the subsequent
administration of scopolamine and milameline. These individual
z-transformed FC-maps were loaded in SPM8 and mean zFC-maps
were computed per group. The mean zFC-maps for each seed region
are presented by overlaying them on the EPI-image.
Then, using the individual hippocampus zFC-maps of each animal,
the strength of functional connectivity with the hippocampus, repre-
sented as T-values, was calculated for the thalamus using a mask
for this region. The same was done for the cingulate cortex zFC-maps
of each animal which were used to calculate FC strength with the
retrosplenial cortex, rhinal cortex and visual cortex. Finally, the visual
cortex zFC-maps of each animal were used to calculate FC strength
with the retrosplenial cortex and the rhinal cortex. This allowed to
analyze 6 functional connections i.e. FC between the hippocampus and
thalamus, between the cingulate and retrosplenial cortex, between the
cingulate and rhinal cortex, between the cingulate and visual cortex,
between the visual and retrosplenial cortex and between the visual
and rhinal cortex.
Behavior study
Passive avoidance learning was tested in a step-through box during
the dark phase of the animal's activity cycle. The step-through box
consisted of a ﬁrst, brightly lit compartment connected with a second,
dark compartment by means of a sliding door. Mice were put in the
illuminated compartment, and after 5 s the sliding door connectingboth compartments was opened. Upon complete entry into the dark
compartment (4-paw criterion), animals received a slight foot shock
(0.3 mA, 1 s). Exactly 24 h later, the escape latency to re-enter the
dark compartment was timed up to 300 s. The passive avoidance test
was performed in four groups of animals: a group treated with saline
(N = 8, 10 ml/kg, s.c.), a group treated with scopolamine (N = 8,
1 mg/kg, s.c.), and a group treated with milameline (N = 8, 1 mg/kg,
s.c.). Training for the passive avoidance test was performed 55 min
after injection for these groups. A fourth group was subsequently
treated with scopolamine (N = 12, 1 mg/kg, s.c.) and 25 min later
with milameline (1 mg/kg, s.c.). For this group, training for the passive
avoidance test was performed 55 min after the administration of
scopolamine.Statistics
Pharmacological MRI
Statistical analyses were performed in SPM8. In a ﬁrst level analysis
pre- and post-injection conditions were compared for each subject. In a
second level analysis, paired T-tests were used to compare pre-injection
and post-injection conditions on a group level (uncorrected, p b 0.001).Pharmacological resting-state functional MRI: ROI-based analysis
The statistical analyses for the correlation matrices were performed
using MATLAB. One sample T-tests were performed for the mean
correlation matrices of the saline and scopolamine groups to retain
the signiﬁcant correlations per group. The false discovery rate (FDR)
correction was used to correct for multiple comparisons. Two sample
T-tests were performed for the comparison of two groups to determine
which functional correlations are signiﬁcantly different (p b 0.05, un-
corrected for multiple comparisons). For the saline vs. scopolamine
group, a difference matrix was obtained showing the differences,
represented as T-values, between both groups for all functional corre-
lations. A color map of this matrix was produced in MATLAB, showing
warmer colors for higher T-values i.e. for bigger differences between
the groups.Pharmacological resting-state functional MRI: seed-based correlation
analysis
Mean statistical zFC-maps of each group were obtained in SPM8
using a one-sample T-test and were corrected for multiple comparisons
using a FDR-correction (p b 0.05) and a threshold of at least 20 voxels.
Comparison of the zFC-maps between groups was performed using a
one-way ANOVA with a FDR-correction for multiple comparisons
(p b 0.05) and a threshold of 20 voxels.
For the individual zFC-maps of the left hippocampus, cingulate
cortex or visual cortex seed regions of each animal, a threshold was
set to retain the signiﬁcant functional connections with the seed region
(FDR-correction for multiple comparisons, p b 0.05). The strength of
FC between the seed region and other regions (cfr. Section 2.4.3) is
represented as T-values for each subject and was analyzed in SPSS
(http://www-01.ibm.com/software/be/analytics/spss/). To evaluate
the dose-dependent effect of scopolamine, a one-way Anova was used
with the Tukey correction for multiple comparisons (p b 0.05). To eval-
uate differences between the baseline, scopolamine and milameline
conditions, a one-way Anova within-subject was implemented with
the Tukey correction for multiple comparisons (p b 0.05).Behavior study
The statistical analyses of the passive avoidance testwere performed
in SPSS using a paired T-test (p b 0.05) to evaluate differences between
training and test day for each group.
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Pharmacological MRI
Muscarinic AChRs are present throughout the entire brain i.e. in
cortical areas, the hippocampus, the thalamus etc. Pharmacological
MRI (phMRI) was performed to identify brain regions where scopol-
amine induces T2* MRI signal intensity changes. Fig. 1 shows the
phMRI results; pre-injection vs. post-injection statistical difference
maps were obtained for the saline-injected (10 ml/kg) animals and
the scopolamine-injected (3 mg/kg) animals. The doses were chosen
based on the dose-range used in behavior studies described in the
literature (Agrawal et al., 2009; Rush, 1988). For the saline-injected
group there were no signiﬁcant signal intensity differences between
pre-injection and post-injection. For the scopolamine-injected group
signiﬁcant decreases in signal intensity were observed in several
cortical regions, the hippocampus and the thalamus upon administra-
tion of scopolamine (p = 0.001). Based on these results, regions-of-
interest (ROIs) were chosen for the pharmacological rsfMRI data
analysis.
Pharmacological resting-state functional MRI: the effects of scopolamine on
brain FC
Pharmacological rsfMRI was performed to evaluate the effects
of scopolamine on FC: brain FC of saline-injected (10 ml/kg) and
scopolamine-injected (3 mg/kg) groups was compared using a ROI-
analysis. The ROIs were chosen based on the results of the phMRI and
are shown in Fig. 1 i.e. the orbitofrontal cortex (OFC), the cingulate
cortex (Cg), the somatosensory cortex (SS), the anterior thalamus (T),
the hippocampus (HC), the retrosplenial cortex (Resp), the rhinal cortex
(RC), the auditory cortex (AC) and the visual cortex (VC). The ventral
tegmental area/substantia nigra (VTA/SN)was chosen as control region
as it did not show signiﬁcant signal intensity changes in the phMRI.
Functional connections between these ROIs are represented in
correlation matrices (Fig. 2). Functional connections with the hippo-
campus, cingulate cortex and visual cortex were signiﬁcantly affected
by the administration of scopolamine: the hippocampus–thalamus
(p = 0.004), the cingulate cortex–retrosplenial cortex (p = 0.02),
the cingulate cortex–rhinal cortex (p = 0.03), the cingulate cortex–Fig. 1. PhMRI of the saline and scopolamine group. Thisﬁgure shows ﬁve consecutive slices of th
injected group (N = 10/group). The color scale on the right indicates the T-value i.e. the stre
pharmacological rsfMRI analyses are indicated on the Franklin and Paxinos anatomical mous
4 = anterior thalamus, 5 = hippocampus, 6 = retrosplenial cortex, 7 = rhinal cortex, 8 = auvisual cortex (p = 0.01), the visual cortex–retrosplenial cortex
(p= 0.02) and the visual cortex–rhinal cortex (p = 0.01) functional
connections.
Additionally a seed-based analysis was performed with the left
hippocampus, cingulate cortex or visual cortex as seed regions (Fig. 3).
This analysis resulted in mean zFC-maps for each group showing
all signiﬁcant functional connections with the seed region. For all seed
regions the scopolamine-treated group showed overall signiﬁcantly
decreased FC compared to the saline-injected group (hippocampus,
p b 0.001, FDR corrected; cingulate cortex, p b 0.001, FDR corrected;
visual cortex, p b 0.001, FDR corrected). To account for peripheral effects
of scopolamine on brain FC, a group of animals was injected with
methyl-scopolamine (3 mg/kg), a scopolamine derivative with poor
blood–brain–barrier permeability. The methyl-scopolamine-treated
animals showed no signiﬁcant differences compared to the saline-
treated group (Fig. 3). Compared to the scopolamine-treated animals,
signiﬁcant increases of overall FC were observed for all seed-regions
(hippocampus, p b 0.01, FDR corrected; cingulate cortex, p b 0.05, FDR
corrected; visual cortex, p b 0.01, FDR corrected).
To evaluate whether the functional connections that were signiﬁ-
cantly decreased by scopolamine were affected in a dose-dependent
manner, their FC strength was evaluated at 2 lower doses of
scopolamine (0.5 mg/kg and 1 mg/kg). The measure for FC strength is
a T-value, resulting from the individual FC-maps demonstrating all sig-
niﬁcant FC with the seed region i.e. the hippocampus, cingulate cortex
or visual cortex (cfr. material and methods Section 2.4.3) per subject.
The results (Fig. 4) conﬁrmed a dose-dependent effect of scopolamine
on FC, which reached statistical signiﬁcance starting from the dose of
1 mg/kg for all the assessed functional connections. Furthermore, FC
decreases reached statistical signiﬁcance starting from the lowest dose
of 0.5 mg/kg for FC between the cingulate and rhinal cortex, between
the cingulate and visual cortex and between the visual and rhinal
cortex.
Behavior and pharmacological rsfMRI: recovery of scopolamine-induced
memory deﬁcits and FC disruptions
Next, the passive avoidance behavior test was performed to evaluate
whether scopolamine-induced memory deﬁcits could be reversed
with milameline. Passive avoidance behavior was assessed in thee pre-injection vs. post-injection statistical differencemaps for the saline and scopolamine
ngth of the difference between both conditions. The regions-of-interests chosen for the
e brain atlas: 1 = orbitofrontal cortex, 2 = cingulate cortex, 3 = somatosensory cortex,
ditory cortex, 9 = visual cortex, and 10 = ventral tegmental area/substantia nigra.
Fig. 2. The effect of scopolamine on brain FC. This ﬁgure shows the z-transformed FC matrices of the saline (left) and scopolamine (middle) group (N = 15/group). The color scale
represents the strength of the functional connection. T-values representing the difference between the saline vs. scopolamine group are visualized in a color map (right), where higher
T-values are represented by warmer colors. Abbreviations: OC = orbitofrontal cortex, CC = cingulate cortex, SS = somatosensory cortex, T = thalamus, HC = hippocampus, Resp =
retrosplenial cortex, RC = rhinal cortex, AC = auditory cortex, VC = visual cortex, VTA/SN= ventral tegmental area/substantia nigra, and S = signiﬁcant differences (p b 0.05).
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milameline (1 mg/kg) and in a group which was subsequently injected
with scopolamine (1 mg/kg) and milameline (1 mg/kg). The dose of
1 mg/kg scopolamine was chosen because it induced signiﬁcant FC
differences for the six assessed functional connections. The dose of
1 mg/kg milameline was chosen based on the dose-range used in
behavior studies described in the literature (Schwarz et al., 1999). The
results (Fig. 5) showed a signiﬁcant increase in latency for the saline
(training day 11.2 ± 1.0 s; test day 208 ± 4 s; p = 0.001) and
milameline (training day 24.8 ± 4.8 s; test day 166 ± 50 s; p= 0.02)
injected groups. The scopolamine-injected group showed no signiﬁcant
change in latency (training day 51 ± 12 s; test day 62 ± 27 s). The
group injected subsequently with scopolamine andmilameline showed
an increased latency (training day 32 ± 6 s; test day 103 ± 35 s) that
reached a trend (p= 0.065).
Finally, pharmacological rsfMRI was performed using the same
treatment protocol as the passive avoidance test to determine whether
scopolamine-induced FC deﬁcits could be reversed by milameline.
Pharmacological rsfMRI scans were acquired subsequently at baseline,
after the administration of scopolamine (1 mg/kg) and after the
administration of milameline (1 mg/kg). For all the assessed functional
connections scopolamine signiﬁcantly decreased FC compared to base-
line conditions (Fig. 5). FC between the hippocampus and thalamus,
between the cingulate and retrosplenial cortex and between the visual
and retrosplenial cortexwas completely recovered after the subsequent
administration of milameline. However, FC between the cingulate
and rhinal cortex, between the cingulate and visual cortex and between
the visual and rhinal cortex was not completely recovered by
milameline and still showed signiﬁcant differences with baseline
(Fig. 5).
Discussion
The current study evaluated the effects of cholinergicmodulation on
FC in the mouse brain upon acute administration of the mAChR antago-
nist scopolamine and agonist milameline. This was done using pharma-
cological rsfMRI.
In the present study the hypothesis was that cholinergic modula-
tions could be reﬂected as altered FC in the brain. This means that
modulating the cholinergic system with scopolamine, which blocks
cholinergic transmission, might induce FC disruptions in brain re-
gions with a high abundance of mAChR. The phMRI study showed
scopolamine-induced signal intensity changes in the cortex, the hippo-
campus and partly in the thalamus. It must be noted however that the
signal changes in this part of the thalamus might possibly be due to
spreading of the signal from the hippocampus. The statistical phMRImap did not show the expected extensive signal intensity differences
in all brain regions with a high density of cholinergic receptors. This
could be explained by among others the use of anesthesia, which
suppresses neuronal activation, or regional differences in baseline
perfusion or neuronal activity due to differences in vascular density
or reactivity. Nonetheless, these results are in line with studies
demonstrating a high expression of mAChR proteins in the cortex
and hippocampus using subtype-speciﬁc antibodies (Levey et al.,
1991). The ventral tegmental area/substantia nigra region did not
show signal intensity differences in the phMRI, probably due to the
presence of distortions and the low signal-to-noise ratio. This region
also did not show signiﬁcant FC differences in the pharmacological
rsfMRI analyses.
The pharmacological rsfMRI analyses revealed signiﬁcant
scopolamine-induced decreases of FC between the hippocampus and
thalamus, between the cingulate and retrosplenial cortex, between the
cingulate and rhinal cortex, between the cingulate and visual cortex,
between the visual and retrosplenial cortex and between the visual
and rhinal cortex. This is consistent with functional MRI studies in
human subjects where altered hippocampal activity (Antonova et al.,
2011; Sperling et al., 2002) and functional coherence (Wink et al.,
2006) were observed upon scopolamine administration. Wink et al.
showed increased FC between the hippocampus and frontal regions
while the current study showed decreased FC. These discrepancies
might be explained by differences in brain anatomy between human
and rodents. Wink et al. focused mainly on FC between the hippocam-
pus and frontal gyri, which cannot be identiﬁed in the brains of
lissencephalic animals such as mice. Furthermore, there are metabolic
differences between humans and rodents that might result in different
effects of drugs administered in a similar dose and via the same route
of administration. Despite these differences, Wink et al. still show that
altering cholinergic neurotransmission affects FC in the brain. Although
rsfMRI studies targeting the cholinergic system in rodents are very
limited, there are fMRI studies in rats showing altered brain activity in
frontal regions after the administration of scopolamine (Kocsis et al.,
2014). The cholinergic network is known to be involved in learning
and memory and the functional connections that are affected by
scopolamine are involved in higher cognitive functions such as spatial
memory, episodic memory, contextual memory, attention etc.
(Aggleton et al., 2010; Burwell et al., 2004; Fell et al., 2006a,b;
Fernandez and Tendolkar, 2006; Law and Smith, 2012; Leech and
Sharp, 2014; Lenartowicz and McIntosh, 2005; Marchand et al., 2013;
Teixeira et al., 2006). Countless behavior studies in humans and rodents
(Hasselmo, 2006; Klinkenberg and Blokland, 2010) show that blockade
of cholinergic synaptic transmission leads to disruption of these types of
memory functions (Klinkenberg and Blokland, 2010). The results of the
Fig. 3. Seed-based analyses of the hippocampus, cingulate cortex and visual cortex. This
ﬁgure shows three consecutive slices from themean zFC-maps of the saline, scopolamine
and methyl-scopolamine groups (N = 15/group), showing all signiﬁcant functional
connections with the seed i.e. the left hippocampus, cingulate cortex or visual cortex
(p b 0.05, FDR corrected). The color scale represents the T-value i.e. the strength of the
functional connection.
Fig. 4.Dose-dependent effect of scopolamine on FC. The graphs show the strength of FC±
standard error for the saline (10ml/kg) and scopolamine-injected (0.5; 1; 3mg/kg) group
(N = 15/group) for the functional connection between the hippocampus (HC) and
thalamus (T), the cingulate cortex (CC) and retrosplenial cortex (Resp), the cingulate
cortex and rhinal cortex (RC), the cingulate cortex and visual cortex (VC), the visual cortex
and retrosplenial cortex and between the visual cortex and rhinal cortex. *p b 0.05,
**p b 0.01, *** p b 0.001, and **** p b 0.0001.
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that blocking the cholinergic system with scopolamine induces impair-
ments of contextual memory.The six functional connections that were signiﬁcantly affected by
scopolamine at 3 mg/kg were additionally evaluated at two lower
doses of scopolamine. The results showed a dose-dependent response
of scopolamine on FC which reached statistical signiﬁcance for all func-
tional connections at 1 mg/kg. Additionally, FC between the cingulate
and rhinal cortex, between the cingulate and visual cortex and between
the visual and rhinal cortex was signiﬁcantly decreased by the lowest
dose of 0.5 mg/kg. This could mean that those speciﬁc functional
connections are particularly vulnerable to cholinergic blockade. This is
possibly due to a higher mAChR density in those brain regions. Several
studies conﬁrm a high mAChR density in cortical regions of the rodent
brain (Frey and Howland, 1992; Lein et al., 2007; Mulholland et al.,
1992) but rigorous quantitative analyses of these speciﬁc brain regions
would be necessary to correlate receptor density to the FC results of this
study. Nonetheless, these results show that the effect of cholinergic
blockade on FC can already be observed at lower doses in those regions,
which has implications for early-stage studies in neurodegenerative
diseases. Moreover, these results are consistent with ﬁndings in AD,
where the cholinergic system is severely affected (Bales et al., 2006;
Pepeu and Giovannini, 2004; Schneider et al., 2014; Watanabe et al.,
2009). For example the cingulate cortex, which is a memory region,
consistently shows altered FC (Sheline and Raichle, 2013) in AD
patients. Furthermore, the rhinal cortex and visual cortex are involved
in visual recognition and declarative memory, which is preferentially
affected at an early stage during AD progression (Blaizot et al., 2002).
Next it was evaluated whether scopolamine-induced FC deﬁcits
could be reversed with milameline, which stimulates the cholinergic
system. Milameline has been used in behavior studies where it im-
proved scopolamine- or lesion-induced behavior deﬁcits in rhesus
monkeys and in rodents, (Heidrich et al., 1997; Schwarz et al., 1999).
In the present study this was conﬁrmed inmice using the passive avoid-
ance test, which investigates contextualmemory. The passive avoidance
test showed that scopolamine-induced disruptions of contextual
memory can be partially recuperated with milameline. A clear increase
in latency was observed on the test day which reached a trend, but not
statistical signiﬁcance. The pharmacological rsfMRI analyses showed
that milameline caused an increase in brain FC (Fig. S1), explaining
how it might be able to recover FC decreases induced by scopolamine.
It was established that the effects of scopolamine on brain FC persist
for at least until 1 h after the injection, excluding that expected increase
of FC after milameline treatment is caused by wash-out of scopolamine
(Fig. S2). The pharmacological rsfMRI showed that scopolamine-
induced FC deﬁcits could be completely recovered for FC between the
hippocampus and thalamus, between the cingulate and retrosplenial
cortex and between the visual and retrosplenial cortex. However, for
Fig. 5. Scopolamine-induced behavior and FC deﬁcits can be reversed by milameline.
Upper panel shows the results of the passive avoidance test for the saline (10 ml/kg),
scopolamine (1 mg/kg), milameline (1 mg/kg) treated groups (N = 8/group) and for a
group treated subsequently with scopolamine and milameline (N= 12). ** p b 0.05 and
* p b 0.1. Lower panel shows a graph displaying the strength of the FC at baseline, after
the injection of scopolamine and after the subsequent injection of milameline. FC
strength± standard error are shown for FC between the hippocampus (HC) and thalamus
(T), the cingulate cortex (CC) and retrosplenial cortex (Resp), the cingulate cortex and
rhinal cortex (RC), the cingulate cortex and visual cortex (VC), the visual cortex and
retrosplenial cortex and between the visual cortex and rhinal cortex. *p b 0.05,
**p b 0.01, *** p b 0.001, and **** p b 0.0001.
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visual cortex and between the visual and rhinal cortex milameline
only partially recovered the scopolamine-induced FC deﬁcits. This is
consistent with the results of the behavior study, where milameline
only partially recovered scopolamine-induced behavior deﬁcits.
Contextual memory depends on several brain regions including the
hippocampus (Fanselow, 2000), thalamus (Marchand et al., 2013),
cingulate cortex (Riekkinen et al., 1995), rhinal cortex (Burwell et al.,
2004) and visual cortex (Aquino-Cias et al., 1972). Partial recovery of
passive avoidance behavior by milameline can be explained by the
fact that some functional connections involved in contextual memory
show full recovery, but others only show partial recovery. These results
demonstrate that pharmacological rsfMRI can detect the recovery of
cholinergic blockade by stimulating the cholinergic system. This is
consistent with studies in humans, where cholinesterase inhibitors,
which also stimulate the cholinergic system, improved FC in the cingu-
late cortex (Li et al., 2012) and hippocampus (Pa et al., 2013; Risacher
et al., 2013).
An interesting observation is that the functional connections that
already showed decreased FC after administration of the lowest dose
of scopolamine (cingulate–rhinal cortex, cingulate–visual cortex, visu-
al–rhinal cortex) could also not be recovered completely bymilameline.
These observations further support the idea that those functional
connections are particularly vulnerable. Furthermore, these functionalconnections might not be easily recovered by treatment, suggesting
that efforts should be made to develop treatment regimes that can
efﬁciently target the cholinergic system in these speciﬁc brain regions.
It has to be taken into account that scopolamine has peripheral
effects on cardiovascular function and causes vasoconstriction
(Klinkenberg and Blokland, 2010). This means that the observed effects
of scopolamine on brain FC are possibly a combination of peripheral and
central effects. To evaluate the peripheral effects of scopolamine on
brain FC, a group of mice was administered methyl-scopolamine. This
is a methylated derivative of scopolamine which shows the same
receptor binding characteristics as scopolamine but does not readily
cross the blood–brain–barrier (Klinkenberg and Blokland, 2010).
Several behavior studies that use scopolamine in rodents add an
experimental group that is treated with an equivalent dose of methyl-
scopolamine (Harvey et al., 1983; Pradhan and Roth, 1968). So if
scopolamine induces behavior changes at a given dose and methyl-
scopolamine does not affect behavior at the same dose, it can be
assumed that the effects induced by scopolamine aremediated centrally
and not peripherally. The current study showed that scopolamine
induced FC deﬁcits in the mouse brain at a given dose and methyl-
scopolamine did not induce FC alterations at the same dose. This allows
us to assume that the peripheral effects of scopolamine on cardiovascu-
lar function and vasoconstriction can be excluded, and that the observed
effects are of a central nature. In contrast with the results of this study,
recent work showed that butyl-scopolamine, which is also a derivative
of scopolamine with poor blood–brain–barrier permeability, induced
similar fMRI brain activation changes in the rat brain as scopolamine
(Kocsis et al., 2014). That study concluded that the effects of
scopolamine are probably mainly due to vascular responses. Another
study, however, showed that butyl-scopolamine did not induce brain
activation changes measured with fMRI (Cash et al., 2005). Differences
between these studies include anesthesia protocols i.e. isoﬂurane vs.
alfa-chloralose, route of administration i.e. intravenous vs. intraperito-
neally and dosage. The current study showed that undermedetomidine
sedation methyl-scopolamine did not induce FC deﬁcits in the mouse
brain when administered subcutaneously at a dose of 3 mg/kg, while
the same dose of scopolamine induced marked FC decreases. Therefore,
we can conclude that the effects induced by scopolamine on mouse
brain FC in this study are probably not dominated by peripheral effects.
On one hand, cholinergicmodulators can inﬂuence neuronal activity
at the level of the synapses (Wess, 2004, 2012). This has been demon-
strated by electrophysiological studies showing slowing of neuronal
activity by the administration of scopolamine (Ebert and Kirch, 1998;
Kikuchi et al., 1999; Snaedal et al., 2010). Electrophysiological studies
in mice (Brazhnik et al., 2003, 2004) showed that scopolamine
decreases neuronal ﬁring in the hippocampus. On the other hand,
cholinergic modulators can affect the vasculature directly (Sato and
Sato, 1995). Acetylcholine or cholinergic agonists cause vasodilatation
and cholinergic antagonists cause vasoconstriction. There are ﬁve
types of mAChR i.e. M1–M5 and several studies have tried to unravel
the speciﬁc location and function of each of these receptors in the
brain (Levey et al., 1991; Tice et al., 1996). Scopolamine is a non-
selective mAChR antagonist which means that it binds to all mAChR
subtypes with comparable afﬁnity (Golding and Stott, 1997). Studies
in a M5-receptor knock-out mouse model demonstrated that the
administration of ACh in these mice did not induce any vasodilatation
in the cerebral vasculature, suggesting that the M5-receptor subtype is
responsible for vasoactive functions of ACh in the brain (Yamada et al.,
2001, 2003). So scopolamine will probably induce cerebral vasocon-
striction through the M5 receptor subtype, but synaptic activity will
be modulated through all of the other mAChR subtypes which are
abundantly present throughout the whole brain (Lein et al., 2007).
Consistent with this notion, in AD, soluble amyloid exerts toxic effects
at the level of among others the cholinergic neurons. These toxic effects
inﬂuence synaptic transmission of the cholinergic system in AD pathol-
ogy (Auld et al., 2002; Buttini et al., 2002; Mesulam, 2004; Ohno et al.,
158 D. Shah et al. / NeuroImage 109 (2015) 151–1592004; Yan and Feng, 2004). Furthermore, the eventual loss of choliner-
gic synaptic function will play a considerable role in the CBF decreases
observed in AD patients and mouse models of AD (Kuznetsova and
Schliebs, 2013; Ongali et al., 2010; van Beek and Claassen, 2011). The
BOLD signal depends on among others cerebral blood ﬂow (CBF),
which in turn can be inﬂuenced by changes in neuronal activity at the
level of the synapses or by a direct vasoactive at the level of the brain
vessels. Regarding the cholinergic system, it is not straightforward to
completely separate these two effects.
In conclusion, the present study demonstrates that blocking the
cholinergic system is reﬂected as decreased FC in the mouse brain that
can be detected dose-dependently using pharmacological rsfMRI.
Moreover, stimulating the cholinergic system after blockade can
recover the functional connections that were affected. Some functional
connections could be recovered completely and others only partially,
which correlated with the partial recovery of contextual memory
deﬁcits by cholinergic stimulation. Finally, this study revealed that
some functional connections in the cholinergic network are especially
vulnerable to modulation, which has implications for read-out and
treatment strategies in diseases where the cholinergic system is affect-
ed, like in mouse models of AD. It has to be mentioned that the effect
of acute pharmacological modulations are not necessarily comparable
to the effect of chronicmodulations as in pathological conditions. Future
studies could focus on the effect of chronic modulations of the choliner-
gic system and assess whether they can be reversed by treatment.
Nonetheless, the results of this study have implications for studies in
mouse models of neurodegenerative disorders, where pharmacological
rsfMRI might possibly be used as a non-invasive tool to detect early al-
terations of neurotransmitter systems induced by disease or treatment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neuroimage.2015.01.009.
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